3D-Quantitative Structure-Activity Relationships of HEPT Derivatives as HIV-1 Reverse Transcriptase Inhibitors, Based on Ab Initio Calculations

Journal of Chemical Information and Computer Sciences

Volumn 41, Issue 3, 2001, Pages 848-855

  Hannongbua, Supa ^a   Nivesanond, Kanda ^a   Lawtrakul, Luckhana ^b   Pungpo, Pornpan ^a   Wolschann, Peter ^a  

^a KASETSART UNIVERSITY   (Thailand)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ALGORITHM; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG DESIGN; PREDICTION AND FORECASTING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTUM THEORY;

ALGORITHMS; DRUG DESIGN; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUANTUM THEORY; REVERSE TRANSCRIPTASE INHIBITORS;

CRYSTALLOGRAPHY; DRUG THERAPY; ELECTROSTATICS; ENZYMES; GEOMETRY; OPTIMIZATION;

TRANSCRIPTASE INHIBITORS;

MOLECULAR STRUCTURE;

EID: 0035324943     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci0001278     Document Type: Article

References (37)

1. De Clercq, E. Antiviral Therapy of Human Immunodeficiency Virus Infections. Clin. Microbiol. Rev. 1995, 8, 200-239.
2. Young, S. D. Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Perspect. Drug Descov. Des. 1993, 1, 181-192.
3. De Clereq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies For Intervention With HIV-1 Infections. J. Med. Chem. 1995, 38, 2491-2517.
4. Arnold, E.; Das, K.; Ding, J.; Yadav, P. N. S.; Hsiou, Y.; Boyer, P. L.; Hughes, S. H. Targeting HIV Reverse Transcriptase For Anti-AIDS Drug Design. Drug Des. Discov. 1996, 13, 29-47.
5. Esnouf, R.; Re, J.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Non-Nucleoside Inhibitors. Struct. Biol. 1995, 2, 303-308.
6. Sarafianos, S. G.; Das, K.; Ding, J.; Boyer, P. L.; Hughes, S. H.; Arnold, E. Touching the Hear of HIV-1 Drug Resistance: The Fingers Close Down on the dNTP at the Polymerase Active Site. Chem. Biol. 1999, 6, R137-R146.
7. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R. T.; Balzarini, J.; De Clercq, E. A Novel Lead for Specific Anti-HIV-1 Agents: 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio) thymine. J. Med. Chem. 1989, 32, 2507-2509.
8. Hannongbua, S.; Lawtrakul, L.; Limtrakul, J. Structure-Activity Correlation Study of HIV-1 Inhibitors: Electronic and Molecular Parameters. J. Comput.-Aided Mol. Design. 1996, 10, 145-152.
9. Hannongbua, S.; Lawtrakul, L.; Sotriffer, C. A.; Rode, B. M. Comparative Molecular Field Analysis of HIV-1 Reverse Transcriptase Inhibitors in the Class of 1-[(2-Hydroxyethoxy)-methyl]-6-(phenylthio)thymine. Quant. Struct.-Act. Relat. 1996, 15, 389-394.
10. Kireev, D. B.; Chretien, J. R.; Grierson, D. S.; Monneret, C. A 3D QSAR Study of a Series of HEPT Analogues: The Influence of Conformational Mobility on HIV-1 Reverse Transcriptase Inhibition. J. Med. Chem. 1997, 40, 4257-4264.
11. Luco, J. M.; Ferretti, F. H. QSAR Based on Multiple Linear Regression and PLS Methods for the Anti-HIV Activity of a Large Group of HEPT Derivatives. J. Chem. Inf. Comput. Sci. 1997, 37, 392-401.
12. Tronchet, J. M. J.; Grigorov, M.; Dolatshahi, N.; Moriaud, F.; Weber, J. A QSAR Study Confirming the Heterogeneity of the HEPT Derivative Series Regarding Their Interaction with HIV Reverse Transcriptase. Eur. J. Med. Chem. 1997, 32, 279-299.
13. Lawtrakul, L.; Hannongbua, S. Quantitative Structure-Activity Relationships of HIV-1 RT Inhibitors in the Class of 1-[(2-Hydroxyethoxy)methyl]-5,6-substituted Thymine [HEPT] Analogues. Sci. Pharm. 1999, 67, 43-56.
14. Jalali-Heravi, M.; Parastar, F. Use of Artificial Neural Networks in a QSAR Study of Anti-HIV Activity for a Large Group of HEPT Derivatives. J. Chem. Inf. Comput. Sci. 2000, 40, 147-154.
15. Klein, C. T.; Lawtrakul, L.; Hannongbua, S.; Wolschann, P. Accessible Charges in Structure-Activity Relationships. A Study on HEPT-based HIV-1 RT Inhibitors. Sci. Pharm. 2000, 68, 25-40.
16. Lawtrakul, L.; Hannongbua, S.; Beyer, A.; Wolschann, P. Conformational Study of the HIV-1 Reverse Transcriptase Inhibitor 1-[(2Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). Biol. Chem. 1999, 380, 265-267.
17. Lawtrakul, L.; Hannongbua, S.; Beyer, A.; Wolschann, P. Molecular Calculations on the Conformation of the HIV-1 Reverse Transcriptase Inhibitor 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). Monatsh. Chem. 1999, 130, 1347-1363.
18. Tanaka, H.; Baba, M.; Kayakawa, H.; Sakamaki, T.; Miyasaka, T.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, R. T.; Baizarini, J.; De Clercq, E. A New Class of HIV-1-Specific 6-substituted Acyclouridine Derivatives: Synthesis and Anti-HIV-1 Activity of 5- or 6-substituted Analogues of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J. Med. Chem. 1991, 34, 349-357.
19. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Nitta, I.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Structure-Activity Relationships of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine Analogues: Effect of Substitutions at the C-6 Phenyl Ring and at the C-5 Position on Anti-HIV-1 Activity. J. Med. Chem. 1992, 35, 337-345.
20. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Nitta, I.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and Antiviral Activity of Deoxy Analogues of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as Potent and Selective Anti-HIV-1 Agents. J. Med. Chem. 1992, 35, 4713-4719.
21. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Inouye, N.; Baba, Masanori; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and Antiviral Activity of 6-Benzyl Analogues of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as Potent and Selective Anti-HIV-1 Agents. J. Med. Chem. 1995, 38, 2860-2865.
22. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches, VCH: Weinheim, 1993.
23. Kubinyi, H. 3D-QSAR in Drug Design, Theory, Methods and Applications; ESCOM: Leiden, 1993.
24. Hannongbua, S.; Pungpo, P.; Limtrakul, J.; Wolschann, P. Quantitative Structure-Activity Relationships and Comparative Molecular Field Analysis of TIBO derivatived HIV-1 Reverse Transcriptase Inhibitors. J. Comput.-Aided Mol. Design. 1999, 13, 563-577.
25. Pungpo, P.; Hannongbua, S. Three-Dimensional Quantitative Structure-Activity Relationships Study on HIV-1 Reverse Transcriptase Inhibitors in the Class of Dipyridodiazepinone Derivatives, Using Comparative Molecular Field Analysis. J. Mol. Graph. Mod. 2000, 18, 581-590.
26. Hopkins, A. L.; Ren, J.; Esnouf, R. M.; Willcox, B. E.; Jones, Y.; Ross, C.; Miyasaka, T.; Walker, R. T.; Tanaka, H.; Stammers, D. K.; Stuart, D. I. Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside Inhibitors. J. Med. Chem. 1996, 39, 1589-1600.
27. ALCHEMY2000; Tripos Associates Inc.: St. Louis, MO, 1996.
28. GAUSSIAN94; Carnegie Office Park, Building 6, Pittsburgh, PA, 1995.
29. SYBYL Molecular Modelling Softwares, Version 6.5; Tripos Associates, Inc.: St. Louis, MO, 1998.
30. Wold, S.; Johansson, E.; Cochi, M.; In 3D QSAR in Drug Design, Theory, Methods and Applications; Kubinyi, H., Ed.; ESCOM: Leiden, 1993; pp 523-549.
31. SYBYL Molecular Modelling Softwares, Version 6.3; Tripos Associates, Inc.: St, Louis, MO, 1996; p 229.
32. Proudfoot, J. R.; Hargrave, K. D.; Kapadia, S. R.; Patel, U. R.; Grozinger, K. G.; Mcneil, D. W.; Cullen, E.; Cardozo, M.; Tong, L.; Kelly, T. A.; Rose, J.; David, E.; Mauldin, S. C.; Fuchs, V. U.; Vitous, J.; Hoermann, M.; Klunder, J. M.; Raghavan, P.; Skiles, J. W.; Mui, P.; Richman, D. D.; Sullivan, J. L.; Shih, C.; Grob, P. M.; Adams, J. Novel Non-Nucleoside Inhibitors of Human Imunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase. 4. 2-Substituted Dipyridodiazepinones as Potent Inhibitors of Both Wild-Type and Cysteine-181 HIV-1 Reverse Transcriptase Enzyme. J. Med. Chem. 1995, 38, 4830-4838.
33. Pauwels, R.; Andries, K.; Debyser, Z.; Daele, P. V.; Schols, D.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.; Vandamme, A.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Heykants, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and Highly Selective Human Immunodeficiency Virus Type 1 (HIV-1) Inhibition by a Series of Alpha-Anilinophenylacetamide Derivatives Targeted at HIV-1 Reverse Transcriptase. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 1711-1715.
34. Buckheit, R. W., Jr.; Fliakas-Boltz, V.; Yeagy-Bargo, S.; Weislow, O.; Mayers, D. L.; Boyer, P. L.; Hughes, S. H.; Pan, B.; Chu, S.; Bader, J. P. Resistance to 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine Derivatives is Generated by Mutations at Multiple Sites in the HIV-1 Reverse Transcriptase. Virology 1995, 210, 186-193.
35. Balyarini, J.; Perez-Perez, M.-J.; Velazquez, S.; San-Felix, A.; Camarasa, M.-J.; De Clercq, E.; Karlsson, A. Suppression of the Breakthrough of Human Immunodeficiency Virus Type 1 (HIV-1) in Cell Culture by Thiocarboxanilide Derivatives when Used Individually or in Combination with Other HIV-1-specific Inhibitors (i.e., TSAO Derivatives). Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 5470-5474.
36. Das, K.; Ding, J.; Hsiou, Y.; Clark, A. D., Jr.; Moereels, H.; Koymans, L.; Andries, K.; Pauwels, R.; Janssen, P. A. J.; Boyer, P. L.; Clark, P.; Smith, R. H., Jr.; Smith, M. B. K.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Crystal Structures of 8-C1 and 9-C1 TIBO Complexed with Wild-Type HIV-1 RT and 8-Cl TIBO Complexed with the Tyr181Cys HIV-1 RT Drug-Resistant Mutant. J. Mol. Biol. 1996, 264, 1085-1100.
37. Yu, H.; Das, K.; Ding, J.; Clark, A. D., Jr.; Rösner, M.; Winkler, I.; Riess, G.; Hughes, S. H.; Arnold, E. Structures of Tyr188Leu Mutant and Wild-Type HIV-1 Reverse Transcriptase Complexed with the Non-Nucleoside Inhibitor HBY 097: Inhibitor Flexibility is a Useful Design Feature for Reducing Drug Resistance. J. Mol. Biol. 1998, 284, 313-323.